APYX); The deadline for the lead applicant is August 5, 2022

PHILADELPHIA CREAM, June 30, 2022 /PRNewswire/ — Shepherd Montague is investigating allegations of securities fraud on behalf of investors who purchased Apyx Medical Corporation (“Apyx” or the “Company”) securities (NASDAQ: APYX) Between May 12, 2021 and March 11, 2022 (the “Class Period”).

If you purchased the Apyx securities during the Class Period, would like to discuss At Berger Montague investigation, or if you have any questions regarding your rights or interests, please contact the lawyers Andre Abramowitz at [email protected] or (215) 875-3015, or Michael Dell‘Angelo to [email protected] or (215) 875-3080 or visit: https://investigations.bergermontague.com/apyx-medical-/

Whistleblowers: Anyone with non-public information about Apyx is encouraged to help confidentially At Berger Montague survey or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.

On March 14, 2022, Apyx has revealed that the United States Food and Drug Administration (FDA) will issue a Medical Device Safety Notice (MDSC) regarding the company’s advanced energy products. The Company further revealed that “[b]Based on our initial interactions with the FDA, we believe the Agency’s MDSC will relate to the use of our Advanced Energy products outside of their FDA-approved indication for general use in cutting, coagulation, and soft tissue removal during open and laparoscopic surgical procedures. .”

On this news, Apyx’s stock fell $4.02i.e. 40.6%, to close at $5.88 per share on March 14, 2022on an unusually high volume of transactions.

The Complaint filed in this class action alleges that throughout the Class Period, the Defendants misled investors that: (1) a significant number of Apyx’s Advanced Energy products were used to off-label indications; and (2) these off-label uses have resulted in an increase in the number of medical device reports filed by Apyx of serious adverse events.

Shepherd Montaguewith offices at philadelphia cream, Minneapolis, washington d.c.and San Diegohas been a pioneer in securities class actions since its founding in 1970. Shepherd Montague has represented individual and institutional investors for over five decades and acts as lead counsel before courts across United States.

contacts
Andre Abramowitzsenior counsel
Shepherd Montague
(215) 875-3015
[email protected]

Michael Dell‘Angelo, executive shareholder
Shepherd Montague
(215) 875-3080
[email protected]

THE SOURCE Shepherd Montague